Business Context and Reporting Period
Company: Stryker Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Stryker is a leading global medical technology company with two primary reportable segments: Orthopaedic Implants (joint replacement, trauma, spinal, craniomaxillofacial) and MedSurg Equipment (surgical equipment, navigation, endoscopy, patient handling). The company operates in over 100 countries, with 64% of sales generated domestically and 36% internationally.
Key Financial Metrics (2007)
| Metric | 2007 (in millions) | 2006 (in millions) | Change |
|---|---|---|---|
| Net Sales | $6,000.5 | $5,147.2 | +17% |
| Gross Profit | $4,135.3 | $3,530.6 | +17% |
| Gross Margin | 68.9% | 68.6% | +0.3 pts |
| Operating Income | $1,307.3 | $1,063.6 | +23% |
| Net Earnings (Continuing Ops) | $986.7 | $771.4 | +28% |
| Net Earnings (Total) | $1,017.4 | $777.7 | +31% |
| Diluted EPS (Total) | $2.44 | $1.89 | +29% |
| Operating Cash Flow | $1,028.3 | $867.3 | +19% |
| Long-Term Debt | $16.8 | $14.8 | +13.5% |
| Cash & Marketable Securities | $2,410.8 | $1,414.8 | +71% |
| Working Capital | $3,571.9 | $2,182.8 | +64% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% to $6.0 billion, driven by a 14% increase in unit volume/mix and a 3% favorable impact from foreign currency exchange rates. Orthopaedic Implants sales grew 15%, while MedSurg Equipment sales grew 19%.
- Profitability: Operating income rose 23% to $1.3 billion. Gross margin improved slightly to 68.9% due to manufacturing efficiencies.
- Discontinued Operations: The company sold its outpatient physical therapy business (Physiotherapy Associates) in 2007 for $150 million, resulting in a $25.7 million gain on sale.
- Unusual Items: A $19.8 million charge was recorded for intangible asset impairment related to intervertebral body fusion cage patents following an FDA decision to downgrade certain products. This contrasts with a $52.7 million purchased in-process R&D charge in 2006 related to the Sightline acquisition.
- Liquidity: Cash and marketable securities increased significantly to $2.4 billion, bolstered by strong operating cash flows and the proceeds from the Physiotherapy Associates sale.
Guidance, Outlook, and Risks
2008 Outlook
- Earnings: Management projects diluted net earnings per share for 2008 to approximate $2.88, representing a 22% increase over 2007.
- Sales: Constant currency net sales are projected to increase 11% to 13% in 2008.
- Currency Impact: Management anticipates a favorable impact on net sales of 1% to 1.5% for the full year 2008 if exchange rates hold near year-end 2007 levels.
Risks and Contingencies
- Regulatory Investigations: The company is cooperating with an informal SEC inquiry regarding potential Foreign Corrupt Practices Act violations and a DOJ Antitrust Division subpoena regarding orthopaedic implant sales. A non-prosecution agreement was reached in 2007 regarding consulting contracts with surgeons.
- FDA Compliance: Received two warning letters in 2007 regarding quality system specifications at facilities in Cork, Ireland, and Mahwah, New Jersey.
- Product Liability: Ongoing exposure to product liability claims and potential settlements beyond insurance coverage.
- Reimbursement Pressure: Risk of reduced reimbursement levels from third-party payers and government cost-containment measures.
Investor Verification Checklist
- Regulatory Status: Verify the resolution status of the DOJ Antitrust and SEC Foreign Corrupt Practices Act inquiries and the impact of the FDA warning letters on manufacturing operations.
- Intangible Assets: Review the specific impact of the $19.8 million impairment charge on future R&D pipelines, particularly regarding spinal fusion products.
- Acquisition Integration: Assess the progress of the Sightline Technologies acquisition (flexible endoscopes) and the timeline for commercialization expected in 2008.
- Currency Hedging: Evaluate the effectiveness of the company's forward currency exchange contracts in mitigating the impact of foreign exchange fluctuations on international sales (36% of total revenue).
- Debt Capacity: Confirm the availability of the $1,047.3 million in additional borrowing capacity under existing credit facilities.